- Investing Ideas
- U.S. Pharmaceuticals & Biotech Breakout Stocks
U.S. Pharmaceuticals & Biotech Breakout Stocks
Results
16
Stocks where the price continues to rise after more than a year of consistent gains.
16 companies
AbCellera Biologics
Market Cap: US$3.7b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$11.38
7D
64.2%
1Y
147.9%
Eton Pharmaceuticals
Market Cap: US$1.7b
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$58.86
7D
32.0%
1Y
245.4%
Replimune Group
Market Cap: US$1.4b
A clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom.
REPL
US$14.97
7D
24.1%
1Y
169.2%
Omeros
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
OMER
US$17.19
7D
29.7%
1Y
289.8%
Faeth Therapeutics
Market Cap: US$835.7m
A clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
FTH
US$32.34
7D
32.6%
1Y
272.6%
Assembly Biosciences
Market Cap: US$670.9m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$32.95
7D
23.5%
1Y
29.5%
Camp4 Therapeutics
Market Cap: US$341.4m
A clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
CAMP
US$5.44
7D
28.3%
1Y
225.7%
Cue Biopharma
Market Cap: US$143.7m
A clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders.
CUE
US$34.20
7D
26.1%
1Y
38.0%
RenovoRx
Market Cap: US$63.1m
A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.40
7D
25.0%
1Y
46.5%
Apollomics
Market Cap: US$51.4m
A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
APLM
US$23.40
7D
38.5%
1Y
312.7%
Brainstorm Cell Therapeutics
Market Cap: US$10.9m
A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
BCLI
US$0.99
7D
25.7%
1Y
58.3%
AquaBounty Technologies
Market Cap: US$7.6m
Operates as a land-based aquaculture company.
AQB
US$1.49
7D
26.9%
1Y
106.3%
GB Sciences
Market Cap: US$211.8k
A plant-based research and biopharmaceutical drug development company.
GBLX
US$0.0004
7D
33.3%
1Y
300.0%
Medicine Man Technologies
Market Cap: US$171.2k
Medicine Man Technologies, Inc., doing business as Schwazze, engages in the cultivation, manufacturing, distribution, and retail sale of cannabis and cannabis related products in Colorado and New Mexico.
SHWZ
US$0.002
7D
199,900.0%
1Y
100.0%
U.S. Stem Cell
Market Cap: US$66.2k
Engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally.
USRM
US$0.0001
7D
900.0%
1Y
9,900.0%
Hero Technologies
Market Cap: US$56.4k
Operates as an early-stage cannabis company.
HENC
US$0.0001
7D
9,900.0%
1Y
0%